Genmab reported 23.18B in Current Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agios Pharmaceuticals AGIO:US $ 1064.23M 241.05M
AstraZeneca AZN:LN 26.24B 447M
Bayer BAYN:GR 32.58B 633M
Galapagos GLPG:NA 4.86B 154.14M
Genmab GEN:DC 23.18B 439M
GRIFOLS GRF:SM € 3239.5M 153.93M
Hikma Pharmaceutical HIK:LN 2.09B 139M
Immunogen IMGN:US $ 456.72M 22.03M
Lonza Group LONN:SW 5.96B 925M
Novartis NOVN:VX 45.72B 19.46B
William Demant Holding WDH:DC 7.89B 395M